Clinical trial · Interventional
Screening for Prostate Cancer Among Those Prostate-specific Antigen Value Between 2.5 and 4.0 ng/mL
Screening for Prostate Cancer Among Those Initial Prostate-specific Antigen Value Between 2.5 and 4.0 ng/mL
NCT04317625CI-TRIAL-00044169unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study aims to evaluate the detection rate and characteristics of prostate cancer among males with PSA values between 2.5 and 4.0 ng/mL in Nanjing, meanwhile, to access the effectiveness of conducting multi-parametric MRI (mpMRI) after PSA assay.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| mpMRI scanning | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- participants
- description
- All of the participants tested serum PSA, some of them conducted mpMRI with/without prostate biopsy under instruction.
- interventionNames
- Diagnostic Test: mpMRI scanning
Primary outcomes (1)
- measure
- Incidence of prostate cancer
- timeFrame
- 3 years
- description
- among PSA between 2.5 and 4.0 ng/ml
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 50 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 50 * PSA between 2.5 and 4.0ng/ml * (Eastern Cooperative Oncology Group)ECOG grade: 0-1 * Normal organic function indexes: * (absolute neutrophil count)ANC ≧1.5×109/L * (platelet count)PLT ≧100×109/L * Hb ≧90 g/L * (total bilirubin)TBIL ≦1.5×ULN * (aspartate aminotransferase)ALT≦2.5×ULN * (alanine aminotransferase)AST ≦2.5×ULN * (blood urea nitrogen)BUN (orUREA) and Cr ≦1.5×ULN Exclusion Criteria: * Former serum PSA detection * Having took Proscar in the past 3 months * Suffered from any other malignant tumor in the past 5 years * History of acute urinary retention, acute or chronic bacterial or abacterial prostatitis within 6 weeks or other recent infection of the urinary system
References
Publications (0)
Data not yet available
No reference posted for this study.